Cargando…
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417287/ https://www.ncbi.nlm.nih.gov/pubmed/34480015 http://dx.doi.org/10.1038/s41408-021-00544-x |
| _version_ | 1783748346723172352 |
|---|---|
| author | Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli |
| author_facet | Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli |
| author_sort | Chen, Yunxin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8417287 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84172872021-09-08 A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli Blood Cancer J Correspondence Nature Publishing Group UK 2021-09-03 /pmc/articles/PMC8417287/ /pubmed/34480015 http://dx.doi.org/10.1038/s41408-021-00544-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) |
| title | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) |
| title_full | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) |
| title_fullStr | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) |
| title_full_unstemmed | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) |
| title_short | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) |
| title_sort | phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible mm with high-risk features (sgh-mm1) |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417287/ https://www.ncbi.nlm.nih.gov/pubmed/34480015 http://dx.doi.org/10.1038/s41408-021-00544-x |
| work_keys_str_mv | AT chenyunxin aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT gopalakrishnansathishkumar aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT ooimelissa aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT sultanarehena aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT limlihui aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT grigoropoulosnicholas aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT ongshinyeu aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT xumingge aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT chngweejoo aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT gohyeowtee aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT nagarajanchandramouli aphase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT chenyunxin phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT gopalakrishnansathishkumar phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT ooimelissa phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT sultanarehena phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT limlihui phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT grigoropoulosnicholas phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT ongshinyeu phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT xumingge phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT chngweejoo phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT gohyeowtee phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 AT nagarajanchandramouli phase2studyofcarfilzomibcyclophosphamideanddexamethasoneasfrontlinetreatmentfortransplanteligiblemmwithhighriskfeaturessghmm1 |